Ignite Creation Date:
2024-05-05 @ 7:56 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00779519
Status:
COMPLETED
Last Update Posted:
2011-06-27
First Post:
2008-10-23
Brief Title:
Safety Study of the Inhibition of Agouti-related Protein AgRP for the Management of Obesity and Weight Loss
Sponsor:
vTv Therapeutics
Organization:
vTv Therapeutics
Study Overview
Official Title:
A Prospective Double-Blind Randomized Placebo-Controlled Phase IIa Multiple Dose Multicenter Study to Assess Safety and Tolerability of TTP435 in Obese Class 1-2 Subjects Over 8 Weeks of Treatment
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight One of the most studied pathways involves the melanocortin receptor Agouti-related protein AgRP and alpha-melanocyte stimulating hormone alphaMSHhave been shown to play an integral role in food intake and body weight
It is reasonable to speculate that if there is an imbalance of alphaMSH and AgRP exist in obese individuals and inhibiting the activity of AgRP may be of therapeutic benefit in treating obesity
It is reasonable to speculate that if there is an imbalance of alphaMSH and AgRP exist in obese individuals and inhibiting the activity of AgRP may be of therapeutic benefit in treating obesity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None